292 related articles for article (PubMed ID: 9340835)
21. [p53 transgenic and knockout mice].
Oda H
Nihon Rinsho; 2000 Jun; 58(6):1250-4. PubMed ID: 10879049
[TBL] [Abstract][Full Text] [Related]
22. Three germline mutations in the TP53 gene.
Cornelis RS; van Vliet M; van de Vijver MJ; Vasen HF; Voute PA; Top B; Khan PM; Devilee P; Cornelisse CJ
Hum Mutat; 1997; 9(2):157-63. PubMed ID: 9067756
[TBL] [Abstract][Full Text] [Related]
23. [Germline mutations of the p53 gene].
Frebourg T
Pathol Biol (Paris); 1997 Dec; 45(10):845-51. PubMed ID: 9769948
[TBL] [Abstract][Full Text] [Related]
24. [Li-Fraumeni syndrome].
Frebourg T
Bull Cancer; 1997 Jul; 84(7):735-40. PubMed ID: 9339200
[TBL] [Abstract][Full Text] [Related]
25. Low rate of TP53 germline mutations in breast cancer/sarcoma families not fulfilling classical criteria for Li-Fraumeni syndrome.
Evans DG; Birch JM; Thorneycroft M; McGown G; Lalloo F; Varley JM
J Med Genet; 2002 Dec; 39(12):941-4. PubMed ID: 12471212
[No Abstract] [Full Text] [Related]
26. Li-Fraumeni syndrome: not a straightforward diagnosis anymore-the interpretation of pathogenic variants of low allele frequency and the differences between germline PVs, mosaicism, and clonal hematopoiesis.
Batalini F; Peacock EG; Stobie L; Robertson A; Garber J; Weitzel JN; Tung NM
Breast Cancer Res; 2019 Sep; 21(1):107. PubMed ID: 31533767
[TBL] [Abstract][Full Text] [Related]
27. Tumor protein 53 mutations and inherited cancer: beyond Li-Fraumeni syndrome.
Palmero EI; Achatz MI; Ashton-Prolla P; Olivier M; Hainaut P
Curr Opin Oncol; 2010 Jan; 22(1):64-9. PubMed ID: 19952748
[TBL] [Abstract][Full Text] [Related]
28. ATM germline mutations in women with familial breast cancer and a relative with haematological malignancy.
Paglia LL; Laugé A; Weber J; Champ J; Cavaciuti E; Russo A; Viovy JL; Stoppa-Lyonnet D
Breast Cancer Res Treat; 2010 Jan; 119(2):443-52. PubMed ID: 19404735
[TBL] [Abstract][Full Text] [Related]
29. Analysis of p53 tumor suppressor gene in families with multiple glioma patients.
Paunu N; Syrjäkoski K; Sankila R; Simola KO; Helén P; Niemelä M; Matikainen M; Isola J; Haapasalo H
J Neurooncol; 2001 Dec; 55(3):159-65. PubMed ID: 11859970
[TBL] [Abstract][Full Text] [Related]
30. Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome.
Bell DW; Varley JM; Szydlo TE; Kang DH; Wahrer DC; Shannon KE; Lubratovich M; Verselis SJ; Isselbacher KJ; Fraumeni JF; Birch JM; Li FP; Garber JE; Haber DA
Science; 1999 Dec; 286(5449):2528-31. PubMed ID: 10617473
[TBL] [Abstract][Full Text] [Related]
31. Absence of germline mutations in exons 5-9 of the p53 gene in patients with Li-Fraumeni-like (SBLA) and familial adenomatous polyposis heritable cancer syndromes.
Moore SK; Zambrano N; Lynch HT; Lipkin M; Kopelovich L
Cancer Genet Cytogenet; 1996 Sep; 90(2):125-9. PubMed ID: 8830720
[TBL] [Abstract][Full Text] [Related]
32. TP53 and CDKN1A mutation analysis in families with Li-Fraumeni and Li-Fraumeni like syndromes.
Andrade RC; Dos Santos AC; de Aguirre Neto JC; Nevado J; Lapunzina P; Vargas FR
Fam Cancer; 2017 Apr; 16(2):243-248. PubMed ID: 27714481
[TBL] [Abstract][Full Text] [Related]
33. Prevalence of germline mutations in the TP53 gene in patients with early-onset breast cancer in the Mexican population.
Gallardo-Alvarado LN; Tusié-Luna MT; Tussié-Luna MI; Díaz-Chávez J; Segura YX; Bargallo-Rocha E; Villarreal C; Herrera-Montalvo LA; Herrera-Medina EM; Cantu-de Leon DF
BMC Cancer; 2019 Feb; 19(1):118. PubMed ID: 30709381
[TBL] [Abstract][Full Text] [Related]
34. Genetic heterogeneity in breast cancer susceptibility.
Andersen TI
Acta Oncol; 1996; 35(4):407-10. PubMed ID: 8695152
[TBL] [Abstract][Full Text] [Related]
35. Development of spontaneous mammary tumors in BALB/c p53 heterozygous mice. A model for Li-Fraumeni syndrome.
Kuperwasser C; Hurlbut GD; Kittrell FS; Dickinson ES; Laucirica R; Medina D; Naber SP; Jerry DJ
Am J Pathol; 2000 Dec; 157(6):2151-9. PubMed ID: 11106587
[TBL] [Abstract][Full Text] [Related]
36. TP53 germline mutation testing in early-onset breast cancer: findings from a nationwide cohort.
Bakhuizen JJ; Hogervorst FB; Velthuizen ME; Ruijs MW; van Engelen K; van Os TA; Gille JJ; Collée M; van den Ouweland AM; van Asperen CJ; Kets CM; Mensenkamp AR; Leter EM; Blok MJ; de Jong MM; Ausems MG
Fam Cancer; 2019 Apr; 18(2):273-280. PubMed ID: 30607672
[TBL] [Abstract][Full Text] [Related]
37. Effects of genetic background on tumorigenesis in p53-deficient mice.
Donehower LA; Harvey M; Vogel H; McArthur MJ; Montgomery CA; Park SH; Thompson T; Ford RJ; Bradley A
Mol Carcinog; 1995 Sep; 14(1):16-22. PubMed ID: 7546219
[TBL] [Abstract][Full Text] [Related]
38. Late-onset common cancers in a kindred with an Arg213Gln TP53 germline mutation.
Ruijs MW; Verhoef S; Wigbout G; Pruntel R; Floore AN; de Jong D; van T Veer LJ; Menko FH
Fam Cancer; 2006; 5(2):169-74. PubMed ID: 16736287
[TBL] [Abstract][Full Text] [Related]
39. [Li-Fraumeni syndrome and germ-line mutations of the p53 gene].
Leblanc T; Soussi T
Arch Pediatr; 1994 Jan; 1(1):61-70. PubMed ID: 8087224
[TBL] [Abstract][Full Text] [Related]
40. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer.
Walsh T; Casadei S; Coats KH; Swisher E; Stray SM; Higgins J; Roach KC; Mandell J; Lee MK; Ciernikova S; Foretova L; Soucek P; King MC
JAMA; 2006 Mar; 295(12):1379-88. PubMed ID: 16551709
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]